Charles Schwab’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-49,296
| Closed | -$1.07M | – | 3619 |
|
|
2022
Q4 | $1.07M | Buy |
49,296
+2,462
| +5% | +$52K | ﹤0.01% | 2756 |
|
|
2022
Q3 | $907K | Buy |
46,834
+515
| +1% | +$10.7K | ﹤0.01% | 2819 |
|
|
2022
Q2 | $920K | Buy |
46,319
+172
| +0.4% | +$4.54K | ﹤0.01% | 2830 |
|
|
2022
Q1 | $1.38M | Buy |
46,147
+375
| +0.8% | +$11K | ﹤0.01% | 2755 |
|
|
2021
Q4 | $1.07M | Buy |
45,772
+1,358
| +3% | +$36.1K | ﹤0.01% | 2884 |
|
|
2021
Q3 | $1.39M | Buy |
44,414
+1,910
| +4% | +$59.1K | ﹤0.01% | 2775 |
|
|
2021
Q2 | $1.5M | Sell |
42,504
-337
| -0.8% | -$11K | ﹤0.01% | 2804 |
|
|
2021
Q1 | $1.51M | Buy |
42,841
+782
| +2% | +$28.9K | ﹤0.01% | 2727 |
|
|
2020
Q4 | $1.58M | Buy |
42,059
+9,077
| +28% | +$330K | ﹤0.01% | 2661 |
|
|
2020
Q3 | $1.1M | Sell |
32,982
-1,347
| -4% | -$39.2K | ﹤0.01% | 2653 |
|
|
2020
Q2 | $910K | Buy |
34,329
+1,576
| +5% | +$37.2K | ﹤0.01% | 2652 |
|
|
2020
Q1 | $537K | Buy |
32,753
+4,221
| +15% | +$92.8K | ﹤0.01% | 2688 |
|
|
2019
Q4 | $726K | Buy |
28,532
+3,549
| +14% | +$71K | ﹤0.01% | 2698 |
|
|
2019
Q3 | $500K | Buy |
24,983
+1,407
| +6% | +$36.4K | ﹤0.01% | 2803 |
|
|
2019
Q2 | $761K | Buy |
23,576
+3,136
| +15% | +$105K | ﹤0.01% | 2667 |
|
|
2019
Q1 | $659K | Buy |
20,440
+1,341
| +7% | +$36.1K | ﹤0.01% | 2668 |
|
|
2018
Q4 | $469K | Hold |
19,099
| – | – | ﹤0.01% | 2795 |
|
|
2018
Q3 | $630K | Hold |
19,099
| – | – | ﹤0.01% | 2763 |
|
|
2018
Q2 | $679K | Buy |
+19,099
| New | +$619K | ﹤0.01% | 2697 |
|
Other funds holding ALBO
Charles Schwab's ALBO Position: Q1 2023 in Review
Charles Schwab sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 49,296 shares — an estimated $1.07M sold.
Charles Schwab first reported a position in ALBO in Q2 2018 and held it in 19 quarters. The position peaked at $1.58M in Q4 2020. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- Charles Schwab reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- Charles Schwab sold 49,296 Albireo Pharma Inc shares in Q1 2023, an estimated $1.07M.
- Charles Schwab first reported a position in Albireo Pharma Inc in Q2 2018 and held it in 19 quarters.
- Charles Schwab's Albireo Pharma Inc position peaked at $1.58M in Q4 2020.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.